HEADER IMMUNE SYSTEM 21-JUL-07 2JT9 TITLE NMR STRUCTURE OF IMMUNOSUPPRESSORY PEPTIDE CONTAINING CYCLOLINOPEPTIDE TITLE 2 X AND ANTENNAPEDIA(43-58) SEQUENCES COMPND MOL_ID: 1; COMPND 2 MOLECULE: 5-MER IMMUNOSUPPRESSORY PEPTIDE FROM CYCLOLINOPEPTIDE X; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: MODIFIED 16-MER IMMUNOSUPPRESSORY PEPTIDE FROM HOMEOTIC COMPND 7 PROTEIN ANTENNAPEDIA; COMPND 8 CHAIN: B; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 OTHER_DETAILS: SOLID PHASE PEPTIDE SYNTHESIS, FMOC STRATEGY; SOURCE 4 MOL_ID: 2; SOURCE 5 SYNTHETIC: YES; SOURCE 6 OTHER_DETAILS: SOLID PHASE PEPTIDE SYNTHESIS, FMOC STRATEGY KEYWDS HELIX, CYCLOLINOPEPTIDE, IMMUNOSUPRESSION, ANTENNAPEDIA(43-58), KEYWDS 2 IMMUNE SYSTEM EXPDTA SOLUTION NMR NUMMDL 19 AUTHOR L.JAREMKO,M.JAREMKO,I.ZHUKOV,M.CEBRAT REVDAT 4 15-NOV-23 2JT9 1 REMARK LINK ATOM REVDAT 3 03-AUG-11 2JT9 1 HETATM REVDAT 2 24-FEB-09 2JT9 1 VERSN REVDAT 1 29-JUL-08 2JT9 0 JRNL AUTH L.JAREMKO,M.JAREMKO,I.ZHUKOV,M.CEBRAT,Z.SZEWCZUK JRNL TITL NMR STRUCTURE OF IMMUNOSUPPRESSORY PEPTIDE CONTAINING JRNL TITL 2 CYCLOLINOPEPTIDE X AND ANTENNAPEDIA(43-58) SEQUENCES JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NMRPIPE, CNS 1.2 REMARK 3 AUTHORS : DELAGLIO, GRZESIEK, VUISTER, ZHU, PFEIFER AND BAX REMARK 3 (NMRPIPE), BRUNGER, ADAMS, CLORE, GROS, NILGES AND REMARK 3 READ (CNS) REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2JT9 COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 13-SEP-07. REMARK 100 THE DEPOSITION ID IS D_1000100261. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298 REMARK 210 PH : 5.5 REMARK 210 IONIC STRENGTH : 0.15 REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 2.5 MM POLYPEPTIDE, METHANOL REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-13C HSQC; 2D 1H-1H TOCSY; REMARK 210 2D 1H-1H ROESY REMARK 210 SPECTROMETER FIELD STRENGTH : 500 MHZ REMARK 210 SPECTROMETER MODEL : UNITYPLUS REMARK 210 SPECTROMETER MANUFACTURER : VARIAN REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : SPARKY, CNS 1.2 REMARK 210 METHOD USED : TORSION ANGLE DYNAMICS, REMARK 210 SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 19 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LOWEST REMARK 210 ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O ASN B 16 N NLE B 19 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 ILE A 4 45.27 22.84 REMARK 500 1 LYS B 11 45.75 -75.16 REMARK 500 1 NAL B 13 -83.88 -151.02 REMARK 500 1 ARG B 17 25.01 49.16 REMARK 500 1 ARG B 18 -27.05 88.87 REMARK 500 1 NLE B 19 -54.14 -142.99 REMARK 500 1 LYS B 20 -78.59 -93.56 REMARK 500 1 NAL B 21 120.22 -176.54 REMARK 500 1 LYS B 22 -75.23 -176.21 REMARK 500 2 ILE A 4 -54.46 52.56 REMARK 500 2 LEU A 5 -68.67 -20.42 REMARK 500 2 LYS B 11 45.72 -74.42 REMARK 500 2 NAL B 13 -79.23 -149.68 REMARK 500 2 ARG B 17 18.26 56.11 REMARK 500 2 ARG B 18 -23.72 94.14 REMARK 500 2 NLE B 19 -42.97 -147.90 REMARK 500 2 LYS B 20 -76.45 -105.89 REMARK 500 2 NAL B 21 119.63 -175.44 REMARK 500 2 LYS B 22 -83.16 -175.94 REMARK 500 3 ILE A 4 -85.77 40.90 REMARK 500 3 LEU A 5 -96.02 26.40 REMARK 500 3 LYS B 11 43.59 -75.75 REMARK 500 3 NAL B 13 -80.40 -151.42 REMARK 500 3 ARG B 18 -23.77 95.05 REMARK 500 3 NLE B 19 -44.69 -152.21 REMARK 500 3 LYS B 20 -80.63 -98.44 REMARK 500 3 NAL B 21 118.17 -176.46 REMARK 500 3 LYS B 22 -80.67 -171.98 REMARK 500 4 ILE A 4 -48.82 55.02 REMARK 500 4 LYS B 11 41.75 -73.19 REMARK 500 4 NAL B 13 -81.89 -148.37 REMARK 500 4 ARG B 18 -23.93 87.14 REMARK 500 4 NLE B 19 -51.74 -143.64 REMARK 500 4 LYS B 20 -76.79 -100.89 REMARK 500 4 NAL B 21 120.05 -174.98 REMARK 500 4 LYS B 22 -81.73 -175.95 REMARK 500 5 ILE A 4 -59.89 50.41 REMARK 500 5 LEU A 5 -82.14 -8.02 REMARK 500 5 LYS B 11 45.77 -72.94 REMARK 500 5 NAL B 13 -78.30 -150.28 REMARK 500 5 ARG B 17 18.36 56.52 REMARK 500 5 ARG B 18 -22.18 95.22 REMARK 500 5 NLE B 19 -47.66 -151.35 REMARK 500 5 LYS B 20 -78.18 -98.66 REMARK 500 5 NAL B 21 119.02 -177.26 REMARK 500 5 LYS B 22 -90.71 -173.91 REMARK 500 6 ILE A 4 -52.46 67.95 REMARK 500 6 LEU A 5 179.79 -48.28 REMARK 500 6 LYS B 11 42.34 -72.75 REMARK 500 6 NAL B 13 -78.07 -147.18 REMARK 500 REMARK 500 THIS ENTRY HAS 175 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ABU A 1 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACA A 7 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NH2 B 24 REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE SEQUENCES OF THE CHAIN A AND B ARE COVALENTLY LINKED REMARK 999 BY ACA-7. ABU-1 AND NH2-24 ARE COVALENTLY LINKED AT THE REMARK 999 N-TERMINUS OF CHAIN A AND THE C-TERMINUS OF CHAIN B, REMARK 999 RESPECTIVELY. THE LINKS BETWEEN ACA/ABU/NH2 AND OTHER REMARK 999 RESIDUES DO NOT BELONG TO REGULAR PEPTIDE LINKING. REMARK 999 THE WHOLE SEQUENCES REPRESENT IMMUNOSUPPRESSORY PEPTIDE REMARK 999 CONTAINING CYCLOLINOPEPTIDE X AND ANTENNAPEDIA. CHAIN B REMARK 999 MATCHES TO THE UNIPROTKB/SWISS-PROT ENTRY P02833 HOMEOTIC REMARK 999 PROTEIN ANTENNAPEDIA RESIDUES 339-354, WITH THE FOLLOWING REMARK 999 MODIFICATIONS:TRP-344 -> NAL, MET-350 -> NLE, TRP-352 -> REMARK 999 NAL. DBREF 2JT9 A 2 6 PDB 2JT9 2JT9 2 6 DBREF 2JT9 B 8 24 PDB 2JT9 2JT9 8 24 SEQRES 1 A 5 PRO PRO ILE LEU LEU SEQRES 1 B 17 ARG GLN ILE LYS ILE NAL PHE GLN ASN ARG ARG NLE LYS SEQRES 2 B 17 NAL LYS LYS NH2 MODRES 2JT9 NAL B 13 ALA BETA-(2-NAPHTHYL)-ALANINE MODRES 2JT9 NLE B 19 LEU NORLEUCINE MODRES 2JT9 NAL B 21 ALA BETA-(2-NAPHTHYL)-ALANINE HET NAL B 13 26 HET NLE B 19 19 HET NAL B 21 26 HET NH2 B 24 3 HET ABU A 1 15 HET ACA A 7 19 HETNAM NAL BETA-(2-NAPHTHYL)-ALANINE HETNAM NLE NORLEUCINE HETNAM NH2 AMINO GROUP HETNAM ABU GAMMA-AMINO-BUTANOIC ACID HETNAM ACA 6-AMINOHEXANOIC ACID HETSYN ABU GAMMA(AMINO)-BUTYRIC ACID HETSYN ACA AMINOCAPROIC ACID FORMUL 2 NAL 2(C13 H13 N O2) FORMUL 2 NLE C6 H13 N O2 FORMUL 2 NH2 H2 N FORMUL 3 ABU C4 H9 N O2 FORMUL 4 ACA C6 H13 N O2 HELIX 1 1 NAL B 13 ARG B 17 5 5 LINK C ABU A 1 N PRO A 2 1555 1555 1.35 LINK C LEU A 6 N ACA A 7 1555 1555 1.33 LINK C ACA A 7 N ARG B 8 1555 1555 1.33 LINK C ILE B 12 N NAL B 13 1555 1555 1.35 LINK C NAL B 13 N PHE B 14 1555 1555 1.34 LINK C ARG B 18 N NLE B 19 1555 1555 1.35 LINK C NLE B 19 N LYS B 20 1555 1555 1.35 LINK C LYS B 20 N NAL B 21 1555 1555 1.34 LINK C NAL B 21 N LYS B 22 1555 1555 1.33 LINK C LYS B 23 N NH2 B 24 1555 1555 1.33 SITE 1 AC1 3 PRO A 2 PRO A 3 GLN B 9 SITE 1 AC2 5 PRO A 2 LEU A 5 LEU A 6 ARG B 8 SITE 2 AC2 5 LYS B 20 SITE 1 AC3 6 ILE B 12 PHE B 14 ARG B 17 ARG B 18 SITE 2 AC3 6 LYS B 22 LYS B 23 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1